Trials / Completed
CompletedNCT02796872
The Effect of Feeding Infant Formula With Bimuno Galactooligosaccharide (GOS)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 392 (actual)
- Sponsor
- Clasado · Industry
- Sex
- All
- Age
- 12 Days – 18 Days
- Healthy volunteers
- Accepted
Summary
This survey is a multicenter, double-blind, randomized, controlled, parallel-designed, prospective trial and is intended to evaluate the Bimuno GOS effects on growth, tolerance, gut health, fecal flora and immune function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | GOS | GOS resource (β-galactosidase from Bacillus circulans) Commercial infant formula containing 4% w/w FOS:GOS (1:3) |
| DIETARY_SUPPLEMENT | B-GOS 3% | Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 3% w/w FOS:B -GOS (1:2) |
| DIETARY_SUPPLEMENT | B-GOS 2% | Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 4% w/w FOS:B -GOS (1:3) |
| DIETARY_SUPPLEMENT | Mother's breast milk | exclusively breastfed infants for at least 7 days prior to enrollment |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2016-12-01
- Completion
- 2017-05-01
- First posted
- 2016-06-13
- Last updated
- 2017-07-19
Source: ClinicalTrials.gov record NCT02796872. Inclusion in this directory is not an endorsement.